Skip to content

Proliv™Rx System

by Neurolief, Ltd.

PMA P250010

Active United States

PMA

Valid until

No expiry

PMA approval is not time-limited

FDA recalls

None found

in data synced 25 Oct 2026

Documents

PMA P250010↗

FDA record

Trust

Unverified

Source FDA PMA, synced 25 Oct 2026.

Regulatory status

as of registry sync 25 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPPR Approved NumberP250010 Date31 Dec 2025ApprovedStatusActive

Official records

From the FDA record

FDA PMA P250010

Received by the FDA
26 Mar 2025
FDA decision
31 Dec 2025
FDA review time
280 days from receipt to decision
Approval order statement, verbatim
The Proliv™Rx System provides focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) treatment. It is intended as an adjunctive treatment for Major Depressive Disorder (MDD) in adults who failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in clinic. It is a prescription-only device.

From the FDA PMA record P250010 (openFDA), as read on 25 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA PMA Active

Specification

PMA

Generic name
Cranial electrotherapy stimulator to treat depression
FDA applicant
Neurolief , Ltd.
PMA number
FDA product code
JXK
Device class
Class III
Regulation
21 CFR Part 882.5800
Advisory committee
Neurology
FDA decision
APPR Approved

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The ProlivRx System is a Cranial Electrotherapy Stimulator designed to deliver focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS). It is classified as a Class III device under FDA regulations and is intended for adjunctive treatment of Major Depressive Disorder (MDD) in adults who have not responded adequately to prior antidepressant therapy.

The device is supplied as a prescription-only system for use in either home or clinical settings. It is not described as single-use or reusable, and no sterility or MRI safety information is provided in the specifications. The ProlivRx System is authorized under FDA PMA (P250010) and falls under the product code JXK, with registration numbers 3019551144, 3015088397, and 3040334342.

Devices cleared under P250010

4 devices · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under P250010
UDI-DISize and differences
Proliv Rx Port Pads PAD0004A
Neurolief, Ltd.
PAD0004A / PAD0004A07290018393277
Single use: yes
On the market
Proliv®Rx Mobile Application (Android) SW-APP-1004
Neurolief, Ltd.
SW-APP-1004 / SW-APP-100407290018393253
Single use: no
On the market
Proliv®Rx Mobile Application (iOS) SW-APP-1003
Neurolief, Ltd.
SW-APP-1003 / SW-APP-100307290018393246
Single use: no
On the market
Proliv®Rx System PLV3
Neurolief, Ltd.
PLV0004A / PLV307290018393208
Single use: no
On the market

Other devices from Neurolief, Ltd.

See all devices from Neurolief, Ltd. →